Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

NCT07681596 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07681596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07681596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
March 6, 2031
Enrollment
101 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma